{"id":55243,"date":"2014-10-13T17:55:00","date_gmt":"2014-10-13T21:55:00","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=55243"},"modified":"2023-09-06T15:32:42","modified_gmt":"2023-09-06T20:32:42","slug":"reilly-to-speak-at-napbs-conference","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/reilly-to-speak-at-napbs-conference\/","title":{"rendered":"Reilly to Speak at NAPBS Conference"},"content":{"rendered":"\r\n

Joe Reilly, President of Joe Reilly & Associates, Inc and National Drug Screening<\/strong>, Inc will present at the 2014 National Association of Professional Background Screeners (NAPBS) Annual Conference in Denver, Colorado. \u00a0Reilly\u2019s presentation entitled \u201cIt’s Not Your Father’s Drug Testing Program!\u201d will discuss new trends in workplace drug testing. The presentation will be take place Tuesday, October 21st<\/sup>\u00a0at 10am.<\/p>\r\n\r\n\r\n\r\n

Reilly will discuss\u00a0will discuss new trends in workplace drug testing including:<\/p>\r\n\r\n\r\n\r\n

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Testing for new drugs of abuse \u2013 bath salts, spice, K2 and more<\/p>\r\n\r\n\r\n\r\n

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The important of post-accident drug testing – largest return on investment for employer drug testing programs<\/p>\r\n\r\n\r\n\r\n

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Marijuana \u2013 recreational, medical and drug employer drug free workplace policies<\/p>\r\n\r\n\r\n\r\n

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Electronic chain of custody for non-DOT drug testing, instant drug testing and now for DOT drug testing<\/p>\r\n\r\n\r\n\r\n

\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How companies can increase efficiencies and reduce exposure to liability with employer drug testing programs<\/p>\r\n\r\n\r\n\r\n

Reilly stated, “I am happy to once again be back presenting at NAPBS after many years, I look forward to an engaging discussion on current workplace drug testing trends.”<\/p>\r\n\r\n\r\n\r\n

The National Association of Professional Background Screeners<\/strong> (NAPBS) exists to promote ethical business practices, compliance with the FCRA, equal employment opportunity and state and international consumer protection laws relating to the background screening profession. NAPBS provides educational programs aimed at empowering members to better serve their clients, while adhering to standards of excellence in the background screening profession.<\/p>\r\n\r\n\r\n\r\n

Joseph Reilly has experience since 1993 in the drug and alcohol testing industry. He regularly provides expert witness testimony, consulting and training programs for employers along with collectors, Labs, TPA\u2019s and others in the drug testing industry. Reilly is a current board member of the Drug & Alcohol Testing Industry Association (DATIA merged with\u00a0NDASA<\/a>\u00a0in 2023) and he had the honor and privilege of serving as the Chairman of the DATIA board from 2004 -2008.<\/p>\r\n","protected":false},"excerpt":{"rendered":"

Joe Reilly, President of Joe Reilly & Associates, Inc and National Drug Screening, Inc will present at the 2014 National Association of Professional Background Screeners (NAPBS) Annual Conference in Denver, Colorado. \u00a0Reilly\u2019s presentation entitled \u201cIt’s Not Your Father’s Drug Testing Program!\u201d will discuss new trends in workplace drug testing. The presentation will be take place […]<\/p>\n","protected":false},"author":12,"featured_media":1073,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55243"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=55243"}],"version-history":[{"count":1,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55243\/revisions"}],"predecessor-version":[{"id":118394,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55243\/revisions\/118394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/1073"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=55243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=55243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=55243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}